XARELTO® vascular dose*: The FIRST and ONLY treatment approach indicated to help reduce risk† in patients with PAD post LER1,2
XARELTO® VASCULAR DOSE* IS EXPECTED TO HELP PREVENT ISCHEMIC EVENTS RELATIVE TO BLEEDS CAUSED IN PATIENTS WITH PAD1,2
A favorable balance of benefits and risk was indicated: Compared to placebo,‡ during 10,000 patient-years of treatment, the XARELTO® vascular dose* would be expected to result in 181 fewer primary outcome events and 29 more TIMI major bleeding events.1
CV = cardiovascular; LER = lower extremity revascularization; MI = myocardial infarction; PAD = peripheral arterial disease; TIMI = Thrombolysis in Myocardial Infarction.
*XARELTO® 2.5 mg twice daily plus aspirin (100 mg in clinical trial; 75 mg to 100 mg in practice) once daily.
†Reduction of a composite of myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation of a vascular etiology in patients with PAD, including patients who have recently undergone an LER procedure due to symptomatic PAD.
‡Patients on placebo received aspirin 100 mg once daily.
